GlassScriptPhysician profile
Sara E Frank
NPI 1144569104
$13,588.04
in general payments reported to CMS, 2019-2025
27 companies · $24.15 in 2025
The $24.15 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,341 · 2022: $11K · 2023: $1,506 · 2024: $98.01 · 2025: $24.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.12 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,629.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $747.78 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $496.16 | 2021-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $353.56 | 2021-2023 | Verquvo |
| Pfizer INC. | $337.70 | 2021-2023 | |
| Irhythm Technologies, INC. | $259.20 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.42 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $233.56 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $214.15 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $132.59 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $103.06 | 2021-2023 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $100.67 | 2022-2023 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $85.52 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $80.11 | 2022-2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $79.83 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $67.19 | 2023 | Barostim Neo System |
| Abbott Laboratories | $64.80 | 2021-2025 | Cardiomems |
| Novo Nordisk INC | $62.35 | 2023-2024 | Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $51.43 | 2023 | Onpattro |
| Amarin Pharma, INC. | $48.09 | 2021 | |
| Azurity Pharmaceuticals, INC. | $40.23 | 2023 | Edarbi |
| Kiniksa Pharmaceuticals, LTD. | $36.30 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $30.49 | 2021 | |
| Biotronik INC. | $29.66 | 2022 | |
| Scpharmaceuticals INC. | $21.12 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $19.49 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.